DigestRedComo funciona
Red
/
Empresas
Lo
No verificado

Longboard Pharmaceuticals, Inc.

Sobre qué escribimos

BiotecnologíaCienciaFarmacéuticaMedicina - VariosSalud

16 Comunicados de prensa

Ver todos los comunicados de prensa
12/11/2024
Industria
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)
Fuente
Longboard Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
07/11/2024
Web y redes sociales
Telefonía
Mercado de valores
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Fuente
Longboard Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
14/10/2024
Multimedia
Web y redes sociales
Finanzas
Telefonía
Mercado de valores
Salud
Higiene alimentaria
Medicina - Varios
Farmacéutica
Biotecnología
Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline
Fuente
Longboard Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
04/10/2024
Mercado de valores
Finanzas
Salud
Ciencia
Farmacéutica
Biotecnología
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Fuente
Longboard Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
26/09/2024
Industria
Ciencia
Higiene alimentaria
Comunicación
Medicina - Varios
Biotecnología
Sanidad
Farmacéutica
Salud
Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin in Dravet Syndrome
Fuente
Longboard Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
19/09/2024
Industria
Salud
Higiene alimentaria
Sanidad
Medicina - Varios
Farmacéutica
Biotecnología
Longboard Pharmaceuticals Receives Rare Pediatric Disease Designation and Orphan Drug Designation for Bexicaserin (LP352) in Dravet Syndrome
Fuente
Longboard Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
08/09/2024
Eventos
Industria
Ciencia
Biotecnología
Farmacéutica
Sanidad
Salud
Medicina - Varios
Longboard Pharmaceuticals Announces Positive Interim Analysis Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)
Fuente
Longboard Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
06/09/2024
Mercado de valores
Finanzas
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Fuente
Longboard Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
28/08/2024
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Eventos
Web y redes sociales
Longboard Pharmaceuticals to Participate in Four Upcoming Investor Conferences in September
Fuente
Longboard Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
26/08/2024
Ciencia
Finanzas
Medicina - Varios
Asociaciones/Profesionales
Sanidad
Biotecnología
Farmacéutica
Salud
Eventos
Longboard Pharmaceuticals to Present Late-Breaking and Encore Data at the 15th European Epilepsy Congress
Fuente
Longboard Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0